NO20072795L - Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser - Google Patents

Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser

Info

Publication number: NO20072795L
Authority: NO; Norway
Prior art keywords: inhibitors; protein kinases; pyrazole; pyrimidines useful; compounds
Prior art date: 2004-11-04

Application number

NO20072795A

Other languages

English (en)

Norwegian (no)

Inventor

Dean Stamos

Pan Li

Alex Aronov

Jon Come

Juan-Miguel Jimenez

Ronald Knegtel

Jean-Damien Charrier

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-04

Filing date

2007-06-01

Publication date

2007-06-01

2007-06-01 Application filed by Vertex Pharma filed Critical Vertex Pharma

2007-06-01 Publication of NO20072795L publication Critical patent/NO20072795L/no

Links

102000001253 Protein Kinase Human genes 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
108060006633 protein kinase Proteins 0.000 title abstract 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
150000003230 pyrimidines Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Neurology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)

NO20072795A 2004-11-04 2007-06-01 Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser NO20072795L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US62544604P	2004-11-04	2004-11-04
PCT/US2005/040344 WO2006052913A1 (en)	2004-11-04	2005-11-04	PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES

Publications (1)

Publication Number	Publication Date
NO20072795L true NO20072795L (no)	2007-06-01

Family

ID=35809833

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20072795A NO20072795L (no)	2004-11-04	2007-06-01	Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser

Country Status (20)

Country	Link
US (1)	US7528138B2 (2)
EP (1)	EP1812440B1 (2)
JP (2)	JP5030229B2 (2)
KR (1)	KR20070090172A (2)
CN (1)	CN101094853B (2)
AT (1)	ATE482213T1 (2)
AU (1)	AU2005304784B2 (2)
CA (1)	CA2586375A1 (2)
DE (1)	DE602005023763D1 (2)
DK (1)	DK1812440T3 (2)
ES (1)	ES2354824T3 (2)
IL (1)	IL182893A0 (2)
MX (1)	MX337817B (2)
NO (1)	NO20072795L (2)
NZ (1)	NZ555236A (2)
PT (1)	PT1812440E (2)
RU (1)	RU2417996C2 (2)
SI (1)	SI1812440T1 (2)
WO (1)	WO2006052913A1 (2)
ZA (1)	ZA200704476B (2)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
ATE482213T1 (de) *	2004-11-04	2010-10-15	Vertex Pharma	Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
PT1853588E (pt) *	2005-02-16	2008-08-25	Astrazeneca Ab	Compostos químicos
US20090156617A1 (en) *	2005-05-12	2009-06-18	Northrup Alan B	Tyrosine kinase inhibitors
EP1899323A2 (en) *	2005-05-16	2008-03-19	AstraZeneca AB	Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007046867A2 (en) *	2005-05-19	2007-04-26	Xenon Pharmaceuticals Inc.	Piperidine derivatives and their uses as therapeutic agents
WO2006127587A1 (en) *	2005-05-20	2006-11-30	Vertex Pharmaceuticals Incorporated	Pyrrolopyridines useful as inhibitors of protein kinase
WO2007049041A1 (en) *	2005-10-28	2007-05-03	Astrazeneca Ab	4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
EP2455382B1 (en)	2005-12-13	2016-10-26	Incyte Holdings Corporation	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
GB0601638D0 (en) *	2006-01-27	2006-03-08	Merck Sharp & Dohme	Therapeutic treatment
PE20080403A1 (es) *	2006-07-14	2008-04-25	Amgen Inc	Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en)	2006-07-14	2012-06-12	Amgen Inc.	Fused heterocyclic derivatives and methods of use
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
CA2668286C (en)	2006-11-03	2014-09-16	Pharmacyclics, Inc.	Bruton's tyrosine kinase activity probe and method of using
CN101778825A (zh) *	2007-03-22	2010-07-14	沃泰克斯药物股份有限公司	适用作詹纳斯激酶抑制剂的n-杂环类化合物
WO2008129255A1 (en) *	2007-04-18	2008-10-30	Astrazeneca Ab	5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
UA99459C2 (en) *	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US20100137398A1 (en) *	2007-05-04	2010-06-03	Novartis Ag	Use of hdac inhibitors for the treatment of gastrointestinal cancers
EP3070090B1 (en)	2007-06-13	2018-12-12	Incyte Holdings Corporation	Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CN101878217B (zh) *	2007-09-28	2014-01-15	协和发酵麒麟株式会社	皮肤疾病的预防和/或治疗剂
WO2009064835A1 (en) *	2007-11-16	2009-05-22	Incyte Corporation	4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
NZ586662A (en) *	2007-12-19	2012-08-31	Vertex Pharma	PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
AU2008343813B2 (en) *	2007-12-19	2012-04-12	Amgen Inc.	Inhibitors of PI3 kinase
JP5638961B2 (ja) *	2008-03-13	2014-12-10	ザジェネラルホスピタルコーポレイション	Ｂｍｐシグナル伝達経路のインヒビター
KR20110017445A (ko) *	2008-06-11	2011-02-21	아스트라제네카 아베	암 및 골수증식성 장애의 치료에 유용한 트리시클릭 2,4-디아미노-ｌ,3,5-트리아진 유도체
WO2010031816A1 (en) *	2008-09-19	2010-03-25	Nerviano Medical Sciences S.R.L.	3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES
PT2350075E (pt)	2008-09-22	2014-06-09	Array Biopharma Inc	Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
CN102227422A (zh) *	2008-09-30	2011-10-26	阿斯利康(瑞典)有限公司	杂环jak激酶抑制剂
CN102271515B (zh) *	2008-10-31	2014-07-02	健泰科生物技术公司	吡唑并嘧啶jak抑制剂化合物和方法
GB0821913D0 (en)	2008-12-02	2009-01-07	Price & Co	Antibacterial compounds
JP5775070B2 (ja) *	2009-05-22	2015-09-09	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
SG176111A1 (en) *	2009-05-22	2011-12-29	Incyte Corp	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
CN102448969A (zh) *	2009-05-28	2012-05-09	沃泰克斯药物股份有限公司	C-met蛋白激酶抑制剂
RS57869B1 (sr)	2009-06-17	2018-12-31	Vertex Pharma	Inhibitori replikacije virusa gripa
UA110324C2 (en)	2009-07-02	2015-12-25	Genentech Inc	Jak inhibitory compounds based on pyrazolo pyrimidine
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AR078012A1 (es) *	2009-09-01	2011-10-05	Incyte Corp	Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
PT2473049T (pt)	2009-09-04	2019-03-04	Sunesis Pharmaceuticals Inc	Inibidores de tirosina quinase de bruton
PT3354652T (pt)	2010-03-10	2020-07-20	Incyte Holdings Corp	Derivados de piperidin-4-ilazetidina como inibidores de jak1
WO2011130515A1 (en) *	2010-04-14	2011-10-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
JP5960688B2 (ja)	2010-05-17	2016-08-02	インコゼンセラピューティクスプライベートリミテッド	プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
NZ604708A (en)	2010-05-20	2015-05-29	Array Biopharma Inc	Macrocyclic compounds as trk kinase inhibitors
RS54824B1 (sr)	2010-05-21	2016-10-31	Incyte Holdings Corp	Topikalna formulacija za inhibiciju jak-a
ES2568455T3 (es)	2010-06-01	2016-04-29	Summit Therapeutics Plc	Compuestos para el tratamiento de enfermedad asociada a Clostridium difficile
GB2480814A (en) *	2010-06-01	2011-12-07	Summit Corp Plc	Compounds for the treatment of clostridium difficile-associated disease
CA2818542A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
AU2011343642A1 (en) *	2010-12-16	2013-05-02	Vertex Pharmaceuticals Incorporated	Inhibitors of influenza viruses replication
KR20180084153A (ko) *	2011-06-10	2018-07-24	메르크 파텐트 게엠베하	Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
MY165963A (en)	2011-06-20	2018-05-18	Incyte Holdings Corp	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2012178125A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
UA118010C2 (uk)	2011-08-01	2018-11-12	Вертекс Фармасьютікалз Інкорпорейтед	Інгібітори реплікації вірусів грипу
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
WO2013028263A1 (en) *	2011-08-24	2013-02-28	Glaxosmithkline Llc	Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
EP2831073B1 (en)	2012-03-30	2020-12-09	Rhizen Pharmaceuticals S.A.	Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
AR091273A1 (es) *	2012-06-08	2015-01-21	Biogen Idec Inc	Inhibidores de pirimidinil tirosina quinasa
EP2884978B1 (en) *	2012-08-16	2019-07-17	The Scripps Research Institute	Novel kappa opioid ligands
CN113384546A (zh)	2012-11-15	2021-09-14	因赛特公司	鲁索利替尼的缓释剂型
WO2014081996A1 (en) *	2012-11-23	2014-05-30	Glaxosmithkline Llc	Novel compounds as diacylglycerol acyltransferase inhibitors
SI2941432T1 (en)	2012-12-07	2018-07-31	Vertex Pharmaceuticals Incorporated	2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
TW201501713A (zh) *	2013-03-01	2015-01-16	Kyowa Hakko Kirin Co Ltd	眼炎症性疾病之預防及／或治療劑
WO2014138168A1 (en)	2013-03-06	2014-09-12	Incyte Corporation	Processes and intermediates for making a jak inhibitor
US9682983B2 (en)	2013-03-14	2017-06-20	The Brigham And Women's Hospital, Inc.	BMP inhibitors and methods of use thereof
EP2970289A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Inc.	Compounds useful as inhibitors of atr kinase
WO2014143242A1 (en) *	2013-03-15	2014-09-18	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
JP2016512815A (ja)	2013-03-15	2016-05-09	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
WO2014175370A1 (ja) *	2013-04-25	2014-10-30	塩野義製薬株式会社	ピロリジン誘導体およびそれらを含有する医薬組成物
SG10201801069QA (en)	2013-08-07	2018-03-28	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
HRP20181272T1 (hr)	2013-11-13	2018-10-05	Vertex Pharmaceuticals Incorporated	Postupci priprave inhibitora replikacije virusa influence
RS59144B1 (sr)	2013-11-13	2019-09-30	Vertex Pharma	Inhibitori replikacije virusa influence
WO2015073267A1 (en) *	2013-11-15	2015-05-21	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
CN104650092B (zh) *	2013-11-16	2017-11-10	广东东阳光药业有限公司	取代的杂芳基化合物及其组合物和用途
DK3077397T3 (da)	2013-12-06	2019-12-16	Vertex Pharma	2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
PE20211782A1 (es)	2014-05-23	2021-09-08	Hoffmann La Roche	Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
PL3152212T3 (pl)	2014-06-05	2020-06-15	Vertex Pharmaceuticals Inc.	Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
LT3157566T (lt)	2014-06-17	2019-08-12	Vertex Pharmaceuticals Incorporated	Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
WO2016011019A1 (en)	2014-07-15	2016-01-21	The Brigham And Women's Hospital, Inc.	Compositions and methods for inhibiting bmp
HUE061448T2 (hu)	2014-11-16	2023-07-28	Array Biopharma Inc	(S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
JP6704416B2 (ja)	2015-05-13	2020-06-03	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	インフルエンザウイルスの複製の阻害剤を調製する方法
JP6857617B2 (ja)	2015-05-13	2021-04-14	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	インフルエンザウイルスの複製の阻害剤
HK1258570A1 (zh)	2015-09-30	2019-11-15	Vertex Pharmaceuticals Inc.	使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
CN108697708A (zh)	2015-10-26	2018-10-23	洛克索肿瘤学股份有限公司	Trk抑制剂抗性癌症中的点突变以及与此相关的方法
ES2987474T3 (es)	2016-04-04	2024-11-15	Loxo Oncology Inc	Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
ES2836222T3 (es)	2016-05-18	2021-06-24	Loxo Oncology Inc	Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
AU2017299850B2 (en)	2016-07-18	2021-05-27	University Health Network	Solid forms of TTK inhibitor
JP7214632B2 (ja)	2016-07-21	2023-01-30	バイオジェンエムエーインク．	ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018200855A1 (en)	2017-04-27	2018-11-01	The Brigham And Women's Hospital, Inc.	Novel alk2 inhibitors and methods for inhibiting bmp signaling
PL233595B1 (pl) *	2017-05-12	2019-11-29	Celon Pharma Spolka Akcyjna	Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK
WO2018215389A1 (en)	2017-05-22	2018-11-29	F. Hoffmann-La Roche Ag	Therapeutic compounds and compositions, and methods of use thereof
AR113922A1 (es)	2017-12-08	2020-07-01	Incyte Corp	Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
KR20200116481A (ko) *	2018-01-29	2020-10-12	메르크 파텐트 게엠베하	Gcn2 억제제 및 이의 용도
EP3746071A4 (en)	2018-01-29	2021-09-01	Merck Patent GmbH	GCN2 INHIBITORS AND THEIR USES
EA202091830A1 (ru)	2018-01-30	2020-12-29	Инсайт Корпорейшн	Способы и промежуточные соединения для получения ингибитора jak
MD3773593T2 (ro)	2018-03-30	2024-10-31	Incyte Corp	Tratament hidradenitei supurative utilizând inhibitori ai JAK
JP7504880B2 (ja) *	2018-10-26	2024-06-24	ケロスセラピューティクスインコーポレイテッド	Ａｌｋ２阻害剤の結晶形
CA3124088A1 (en)	2018-12-20	2020-06-25	Incyte Corporation	Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
US12508262B2 (en)	2020-04-30	2025-12-30	Keros Therapeutics, Inc.	Methods of using ALK2 inhibitors
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
WO2022098812A1 (en)	2020-11-04	2022-05-12	Keros Therapeutics, Inc.	Methods of treating iron overload
US20250042873A1 (en) *	2021-08-24	2025-02-06	The Johns Hopkins University	Compositions and methods for treating proteotoxicity-associated diseases
CN116987083A (zh) *	2022-04-25	2023-11-03	杭州健崃生物科技有限公司	吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途
KR102912267B1 (ko)	2023-04-20	2026-01-15	한국화학연구원	신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2291709A1 (en) *	1997-05-30	1998-12-03	Merck & Co., Inc.	Novel angiogenesis inhibitors
US6194410B1 (en) *	1998-03-11	2001-02-27	Hoffman-La Roche Inc.	Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6245759B1 (en) *	1999-03-11	2001-06-12	Merck & Co., Inc.	Tyrosine kinase inhibitors
GB0103926D0 (en) *	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
US7550470B2 (en) *	2002-12-11	2009-06-23	Merck & Co. Inc.	Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
ATE482213T1 (de) *	2004-11-04	2010-10-15	Vertex Pharma	Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine

2005
- 2005-11-04 AT AT05816516T patent/ATE482213T1/de active
- 2005-11-04 ES ES05816516T patent/ES2354824T3/es not_active Expired - Lifetime
- 2005-11-04 CN CN2005800450252A patent/CN101094853B/zh not_active Expired - Fee Related
- 2005-11-04 AU AU2005304784A patent/AU2005304784B2/en not_active Ceased
- 2005-11-04 MX MX2007005439A patent/MX337817B/es active IP Right Grant
- 2005-11-04 ZA ZA200704476A patent/ZA200704476B/xx unknown
- 2005-11-04 EP EP05816516A patent/EP1812440B1/en not_active Expired - Lifetime
- 2005-11-04 DE DE602005023763T patent/DE602005023763D1/de not_active Expired - Lifetime
- 2005-11-04 JP JP2007540144A patent/JP5030229B2/ja not_active Expired - Fee Related
- 2005-11-04 WO PCT/US2005/040344 patent/WO2006052913A1/en not_active Ceased
- 2005-11-04 US US11/266,935 patent/US7528138B2/en not_active Expired - Fee Related
- 2005-11-04 CA CA002586375A patent/CA2586375A1/en not_active Abandoned
- 2005-11-04 KR KR1020077012308A patent/KR20070090172A/ko not_active Ceased
- 2005-11-04 SI SI200531195T patent/SI1812440T1/sl unknown
- 2005-11-04 NZ NZ555236A patent/NZ555236A/en not_active IP Right Cessation
- 2005-11-04 RU RU2007120518/04A patent/RU2417996C2/ru not_active IP Right Cessation
- 2005-11-04 DK DK05816516.8T patent/DK1812440T3/da active
- 2005-11-04 PT PT05816516T patent/PT1812440E/pt unknown
2007
- 2007-05-01 IL IL182893A patent/IL182893A0/en unknown
- 2007-06-01 NO NO20072795A patent/NO20072795L/no not_active Application Discontinuation
2008
- 2008-10-29 JP JP2008278235A patent/JP2009067803A/ja active Pending

Also Published As

Publication number	Publication date
AU2005304784B2 (en)	2011-03-24
HK1113569A1 (en)	2008-10-10
KR20070090172A (ko)	2007-09-05
CN101094853B (zh)	2011-07-13
MX337817B (es)	2011-11-04
IL182893A0 (en)	2007-08-19
DK1812440T3 (da)	2011-01-31
ES2354824T3 (es)	2011-03-18
ZA200704476B (en)	2008-09-25
JP5030229B2 (ja)	2012-09-19
MX2007005439A (es)	2008-02-19
CA2586375A1 (en)	2006-05-18
AU2005304784A1 (en)	2006-05-18
RU2417996C2 (ru)	2011-05-10
DE602005023763D1 (de)	2010-11-04
EP1812440A1 (en)	2007-08-01
US20060135537A1 (en)	2006-06-22
ATE482213T1 (de)	2010-10-15
PT1812440E (pt)	2011-01-25
CN101094853A (zh)	2007-12-26
NZ555236A (en)	2010-10-29
SI1812440T1 (sl)	2011-04-29
JP2008519059A (ja)	2008-06-05
JP2009067803A (ja)	2009-04-02
EP1812440B1 (en)	2010-09-22
RU2007120518A (ru)	2008-12-10
US7528138B2 (en)	2009-05-05
WO2006052913A1 (en)	2006-05-18

Legal Events

Date	Code	Title	Description
2013-06-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20072795L (no)	2007-06-01	Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser
MX2009006700A (es)	2009-06-30	Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
TW200736250A (en)	2007-10-01	Aminopyrimidines useful as kinase inhibitors
ZA200707342B (en)	2009-03-25	Pyrrolopyrimidines useful as inhibitors of protein kinase
TW200633980A (en)	2006-10-01	Pyridones useful as inhibitors of kinases
ATE466580T1 (de)	2010-05-15	Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de)	2010-06-15	Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de)	2007-07-15	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
WO2005028475A3 (en)	2005-06-09	Compositions useful as inhibitors of protein kinases
WO2007095223A3 (en)	2010-06-24	Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
NO20071915L (no)	2007-05-18	Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
UA84930C2 (ru)	2008-12-10	Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
MX2009006690A (es)	2009-07-31	Aminopirimidinas utiles como inhibidores de proteinas cinasas.
ATE450530T1 (de)	2009-12-15	Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
WO2007087283A3 (en)	2007-09-13	Thiophene-carboxamides useful as inhibitors of protein kinases
MX2009004771A (es)	2009-06-17	Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.
ATE542814T1 (de)	2012-02-15	Pyrazinkinaseinhibitoren
MX2009005231A (es)	2009-06-19	Composiciones utiles como inhibidores de proteina cinasa.
WO2007015923A3 (en)	2007-04-19	Benzimidazoles useful as inhibitors of protein kinases
IL179206A0 (en)	2007-03-08	Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same